Phase II/III to evaluate the safety and efficacy of Thai Red Cross Society fibrin sealant compared with commercially available fibrin sealant (TISSEEL) in post-operative air leak. A randomized controlled trial

Start Date01 Nov 2024

Sponsor / Collaborator

Health Systems Research Institute

TCTR20240723010

/ Not yet recruitingPhase 2/3IIT

Phase II/III open-label randomized-controlled trial to evaluate the safety and efficacy of Fibrin sealant Thai Red Cross Society compared with commercially available fibrin sealant (TISSEEL) in pterygium volunteer

Start Date03 Sep 2024

Sponsor / Collaborator

Health Systems Research Institute

CTRI/2023/06/053870

/ Not yet recruitingPhase 2IIT

Randomised controlled trial comparing the efficacy of autologous platelet rich fibrin therapy versus hydrocolloid gel dressing in chronic non-healing cutaneous ulcers, an open label study from Eastern India.

Start Date30 Jun 2023

Sponsor / Collaborator-

100 Clinical Results associated with Fibrin Sealant (Baxter)

100 Translational Medicine associated with Fibrin Sealant (Baxter)

100 Patents (Medical) associated with Fibrin Sealant (Baxter)

956

Literatures (Medical) associated with Fibrin Sealant (Baxter)

01 Feb 2025·Clinical Neurology and Neurosurgery

Role of CT myelography in the diagnosis and management of spontaneous intracranial hypotension

Article

Author: Marc-Antoine, Migaud ; Simon, Henry

INTRODUCTIONSpontaneous intracranial hypotension (SIH) is a secondary cause of headache. Its pathophysiology is complex, and relies mainly on the notion of a localized leak, and thus a loss of cerebrospinal fluid (CSF) in the spinal region. SIH is little known to the medical profession, for which CT myelography is a technique on the rise, allowing to identify and treat the leak using a blood-patch or a fibrin sealant. The aim of the study was to investigate the contribution of CT myelography in the diagnostic and therapeutic management of spontaneous intracranial hypotension, its modalities and population characteristics.MATERIAL AND METHODSA cohort of patients with spontaneous intracranial hypotension who underwent a CT myelography in our department was retrospectively studied. Nineteen patients were included between March 2020 and October 2022.RESULTSCT myelography allowed identification of an etiology in 16 patients (84 %). The etiology of the leak was mainly a dural tear, identified in 11 patients. One diverticulum and 4 CSF-venous fistulas were identified. First targeted injection of fibrin sealant allowed stopped the leak in 12 out of 17 patients.CONCLUSIONCT myelography allows to identify the etiology of the CSF leak and pinpoint its topography. CT guidance can then be used to treat the leak in the same therapeutic timeframe, with greater efficacy during the first targeted injection of fibrin sealant. The current study data showed a high incidence of dural tears, and a significant proportion of venous-dural fistulas, and a low incidence of diverticulum.

01 Jan 2025·Tzu Chi Medical Journal

Application of fibrin sealant in drain-free transoral endoscopic thyroidectomy vestibular approach

Article

Author: Lin, Chung-Ching ; Ye, Ciou-Nan ; Jitpratoom, Pornpeera ; Wu, Hung-Pin ; Lin, Wei-Chieh ; Chou, Yi-Fan

ABSTRACTObjective:The transoral endoscopic thyroidectomy vestibular approach (TOETVA) is a minimally invasive technique. This study aimed to compare the safety of TOETVA with fibrin sealant (Tisseel) and TOETVA with drainage.Materials and Methods:Patients who underwent TOETVA between January 2018 and December 2021 were divided into drainage (n = 20) and Tisseel (n = 30) groups.Results:The primary outcome was the incidence of complications. The secondary outcomes were operative time and postoperative pain. There were no significant differences in patient demographics, tumor size, intraoperative blood loss, and hospitalization days between the two groups. No patient required conversion to open thyroidectomy. The incidence of complications and postoperative pain was similar in the two groups. The operative time for TOETVA with Tisseel was significantly shorter than for TOETVA with drainage (P = 0.038).Conclusion:TOETVA with Tisseel is a safe alternative to TOETVA with drainage, having a short operative time.

05 Nov 2024·Pain Physician Journal

Long-term Investigation of Annulargrams and Intra-annular Fibrin to Treat Chronic Discogenic Low Back Pain and Radiculopathy: 1-, 2-, and 3-Year Outcome Comparisons of Patients with and without Prior Surgery

Article

Author: Boachie-Adjei, Kwadwo ; Wright, Carrie ; Ercole, Patrick M ; Hussey Iv, Francis ; Murrell, William D ; Serwaa-Sarfo, Akua ; Nguyen, Joseph T ; Pauza, Kevin ; Sutton, Jacob

BACKGROUND: Discogenic chronic low back pain (cLBP) and radiculopathy are the most prevalent causes of disability worldwide. Older spine treatments often lack reliability and are associated with adverse events. Among surgical treatment options, discectomies weaken discs, and fusions cause direct damage to adjacent discs, so both treatments accelerate disc degeneration. Other regenerative medicine treatments, including “stem cell” (centrifuged bone marrow aspirate, BMC), and platelet-rich plasma (PRP), lack fibrin’s bio-adhesive properties. Specifically, fibrin is a strong bio-adhesive, so it immediately integrates into disc defects and binds there, becoming a part of the disc and facilitating new disc tissue growth. OBJECTIVES: To evaluate the safety and efficacy of this new pragmatic algorithm that both diagnoses and treats cLBP by (i) first identifying annulus fibrosus tears (fissures) in the region of symptoms and (ii) subsequently treating those tears by introducing fibrin to seal them and facilitate new tissue growth. STUDY DESIGN: Retrospective cohort study that prospectively reported validated measures in a registry. SETTING: Private, single-center, specialized, interventional pain management institution. METHODS: The patients we decided to observe had suffered from cLBP with or without radiculopathy symptoms in their legs for greater than 6 months. Prior to enrollment, all patients underwent physical therapy and at least 4 invasive treatments without relief. Failed treatments included BMC or PRP injections, intradiscal or intraarticular zygapophyseal joints, or combinations of both. Fluoroscopically guided epidural injections of corticosteroids or PRP were additional failed treatments, as were radiofrequency neurotomies in the medial branch. Candidacy for enrollment was based on meeting the aforementioned criteria and by having magnetic resonance image (MRI) screenings (1.5 T) and plain-film radiographs performed 6 months before treatment. In addition, those MRI screenings and radiographs had to rule out the following concomitant conditions: (i) carcinoma, (ii) fracture, (iii) instability, or (iv) severe vertebral canal or intervertebral foramen stenosis. RESULTS: Significant improvement was demonstrated at one, 2, and 3 years after treatment in all outcome measures. The mean duration of low back pain prior to treatment was 11.2 years. Patients’ mean age was 56 years. Thirty percent of the patients were female, and 70% were male. Both the failed surgery cohort and nonsurgery cohort demonstrated significant improvement after fibrin treatment, with the failed surgery cohort realizing greater relative improvement. Significant improvements in the Oswestry disability index (ODI), visual analog scale, and PROMIS® (mental and physical) scores were consistent across age, gender, comorbidity, and exposure status. At the 12-month follow-up, 50% of patients achieved minimal clinically important differences utilizing the ODI. No severe adverse events were reported. LIMITATIONS: Limitations include patient demographic factors, outcome-measure sensitivity, and that the outcomes were reported prospectively and calculated retrospectively as one-, 2-, and 3-year time frames were attained. Although categorical analyses comparing the prior surgical cohort to the nonsurgical cohort were performed, other pre-enrollment treatments were not categorized for comparison. CONCLUSIONS: Intra-annular fibrin bio-adhesive sealant demonstrates the ability to be an effective treatment for alleviating discogenic cLBP and radiculopathy for at least 3 years, even in patients who all failed multiple prior treatments, including discectomy, fusion, disc PRP, or BMC. The results suggest the benefits of fibrin sealant. Future investigations to consider include a randomized double-blind controlled trial and further categorical analyses. KEY WORDS: Low back, radiculopathy, fibrin, disc herniation, degenerative disc, regenerative, annulargram, annulogram

News (Medical) associated with Fibrin Sealant (Baxter)

30 Jan 2024

·www.biospace.com

RION Announces Initiation of Phase 2A Clinical Study for Purified Exosome Product™ (PEP™) in Diabetic Foot Ulcers

RION's Phase 2A clinical trial focuses on evaluating the safety and efficacy of Platelet Exosome Product™ (PEP™) combined with TISSEEL fibrin sealant for treating Diabetic Foot Ulcers (DFU). Diabetic Foot Ulcers, affecting 18.6 million people worldwide each year, significantly impact quality of life and impose substantial economic burdens on healthcare systems. The trial is a key part of RION's broader efforts in regenerative medicine, aiming to address unmet needs in the treatment of chronic conditions such as DFU. ROCHESTER, Minn.--(BUSINESS WIRE)-- RION, a clinical-stage regenerative medicine company, at the forefront of the exosome therapeutic revolution, has officially commenced a Phase 2A study aimed at assessing the efficacy and safety of its exclusive exosome regenerative therapeutic, known as Purified Exosome Product™ (PEP™), for the management of Diabetic Foot Ulcers (DFU). This press release features multimedia. View the full release here: RION, located in Rochester, MN, is internationally recognized for its pioneering advancements in isolating and mass-producing platelet-derived exosomes. (Photo: Business Wire) Diabetic Foot Ulcers affect approximately 18.6 million people worldwide each year1 and are associated with increasing rates of amputation and death. The economic burden of DFUs is substantial, imposing $13 billion in cost on the US public and private healthcare systems.2 The trial is a key part of RION's broader efforts in regenerative medicine, aiming to address unmet needs in the treatment of chronic conditions such as DFU. Building on the success of the Phase 1B study conducted at Mayo Clinic, RION's Phase 2A trial represents a significant step forward in the development of a regenerative biologic for Diabetic Foot Ulcers. This prospective, randomized, multi-center study will involve 40 patients across the United States. Patients will be divided into two cohorts: one receiving standard care and the other treated with PEP™ exosomes, enabling a thorough comparison of outcomes. A positive outcome in the Phase 2A trial has the potential to pave the way for a pivotal study followed by the submission of a Biologics License Application (BLA). PEP™ addresses a significant unmet medical need in the realm of diabetic wound care. Dr. Atta Behfar, Co-founder of RION, said, “The progress we've made in advancing PEP™, reflects our deep commitment to developing powerful exosome therapies that unleash the body’s ability to heal from within. Not only will this study address a critical unmet need in chronic wound care, but it’s a pivotal moment for RION. We are disrupting the boundaries of exosome technology, to develop a new generation of therapies endowed with the potential to truly transform the way we treat complex and incurable diseases.” In the United States, the treatment of DFUs remains a significant challenge in the medical community, with no new biologics approved by the US FDA for diabetic wounds since the late 1990s3. RION is committed to bringing exosome-based therapies to patients as quickly and safely as possible to transform the management and outcomes of this devastating condition. About RION RION was born out of the Mayo Clinic after two decades of research and innovation at that institution. RION is located in Rochester, MN and is internationally recognized for its pioneering advancements in isolating and mass-producing platelet-derived regenerative exosomes into shelf stable PEP™. RION is rewriting the regenerative medicine playbook. Our cutting-edge proprietary biomanufacturing platform crafts the future of regenerative therapy, unlocking the potent secrets within these tiny cellular messengers. RION’s regenerative PEP™ technology will be integral to the therapeutic exosome revolution. About PEP™ RION's Purified Exosome Product™ (PEP™) is a shelf stable product in a lyophilized powder derived from human platelets that contains stabilized platelet-derived regenerative exosomes. PEP™ is an exosome therapeutic that is designed to promote cell growth and formation of new blood vessels, while also reducing inflammation and protecting cells. RION and its scientific collaborators have performed extensive research showing the potential of PEP™ to heal a wide array of damaged tissue. The company is currently evaluating PEP™ in preclinical and clinical studies for several indications. While our focus remains on wound healing, multiple IND-enabling efforts in musculoskeletal, cardiovascular disease, pulmonary disease and women’s health disorders are creating new solutions where current standards of care cannot address unmet clinical needs. About Diabetic Foot Ulcers (DFU) Diabetic foot ulcers (DFUs) are not just wounds. These slow-healing sores on the feet are a brutal consequence of diabetes, inflicting a triple threat: excruciating pain, crippling mobility, and the specter of amputation. The numbers paint a grim picture. Up to 25% of people with diabetes will face a DFU in their lifetime4, and for almost a quarter of them also limb amputation5. In fact, every three and a half minutes in the US, a DFU becomes an amputation6. This isn't just a statistic, it's a story of lives shattered, livelihoods lost, and families forever changed. Many patients endure the agony of recurrences, their lives trapped in a cycle of healing and reopening wounds. And sadly, the shadow of mortality looms large. 40% of DFU sufferers will succumb to the condition7, making it a pervasive silent killer of diabetic communities. The economic cost is equally staggering. DFUs drain healthcare systems, piling on direct treatment expenses and crippling indirect costs from lost productivity and long-term disability. RION's journey is paved with unwavering determination. We seek to break the cycle of pain, loss, and economic burden through application of our next-generation regenerative exosome technology. We will remain undeterred in our pursuit to have PEP™ become the first biologic to be approved for the treatment of DFU in over 25 years. References 1. Armstrong DG, Tan TW, Boulton AJM, Bus SA. Diabetic Foot Ulcers: A Review. JAMA. 2023 Jul 3;330(1):62-75. doi: 10.1001/jama.2023.10578. PMID: 37395769; PMCID: PMC10723802. 2. Rice JB, Desai U, Cummings AK, Birnbaum HG, Skornicki M, Parsons NB. Burden of diabetic foot ulcers for medicare and private insurers. Diabetes Care. 2014;37(3):651-8. doi: 10.2337/dc13-2176. Epub 2013 Nov 1. Erratum in: Diabetes Care. 2014 Sep;37(9):2660. PMID: 24186882. 3. Fang RC, Galiano RD. A review of becaplermin gel in the treatment of diabetic neuropathic foot ulcers. Biologics. 2008 Mar;2(1):1-12. doi: 10.2147/btt.s1338. PMID: 19707423; PMCID: PMC2727777. 4. Yazdanpanah L, Shahbazian H, Nazari I, Arti HR, Ahmadi F, Mohammadianinejad SE, Cheraghian B, Hesam S. Incidence and Risk Factors of Diabetic Foot Ulcer: A Population-Based Diabetic Foot Cohort (ADFC Study)-Two-Year Follow-Up Study. Int J Endocrinol. 2018 Mar 15;2018:7631659. doi: 10.1155/2018/7631659. PMID: 29736169; PMCID: PMC5875034. 5. Liao X, Li SH, El Akkawi MM, Fu XB, Liu HW, Huang YS. Surgical amputation for patients with diabetic foot ulcers: A Chinese expert panel consensus treatment guide. Front Surg. 2022 Nov 8;9:1003339. doi: 10.3389/fsurg.2022.1003339. PMID: 36425891; PMCID: PMC9679004. 6. Amputation Prevention Alliance. (n.d.). Amputation prevention alliance. Amputation Prevention Alliance | ADA. 7. Jeyaraman K, Berhane T, Hamilton M, Chandra AP, Falhammar H. Mortality in patients with diabetic foot ulcer: a retrospective study of 513 cases from a single Centre in the Northern Territory of Australia. BMC Endocr Disord. 2019 Jan 3;19(1):1. doi: 10.1186/s12902-018-0327-2. PMID: 30606164; PMCID: PMC6318899.

Phase 2Drug Approval

11 Jun 2022

·www.prnewswire.com

At 8.6% CAGR, Global Tissue Sealants and Tissue Adhesive Market Size & Share to Surpass USD 2.9 Billion by 2028 | Industry Trends, Growth, Value, Opportunities, Statistics, Analysis & Forecast Report by ZMR

NEW YORK, June 11, 2022 /PRNewswire/ -- As per the Zion Market Research study, The global tissue sealants and tissue adhesive market was worth around USD 1.5 billion in 2021 and is estimated to grow to about USD 2.9 billion by 2028, with a compound annual growth rate (CAGR) of approximately 8.6 percent over the forecast period. The report analyzes the tissue sealants and tissue adhesive market's drivers, restraints/challenges, and the effect they have on the demands during the projection period. In addition, the report explores emerging opportunities in the tissue sealants and tissue adhesive market. Key Industry Insights &Findings of the Tissue Sealants and Tissue Adhesive Market Reports: As per the analysis shared by our research analyst, the Tissue Sealants and Tissue Adhesive Market is expected to grow annually at a CAGR of around 8.6% (2022-2028). Through the primary research, it was established that the Cognitive and Memory Enhancer Drugs Market was valued at approximately USD 1.5Billion in 2021 and is projected to reach roughly USD 2.9 Billion by 2028. Large population and technical advancements, North America accounted for the largest share of tissue sealants and tissue adhesive. State-of-the-art medical research facilities and rising investments in healthcare infrastructure in this region, and also heightened understanding among both physicians & patients relating to therapeutic approaches, enhanced life expectancy, and a rising population will push growing demands for tissue sealants and tissue adhesives in the Asia Pacific region. Zion Market Research published the latest report titled " Tissue Sealants And Tissue Adhesive Market By Product (Natural Or Biological Sealants & Adhesives And Synthetic & Semi-Synthetic Adhesives), By Application (General Surgery, Orthopedic Surgery, Gynecology Surgery, Cardiovascular Surgery, Cosmetic Surgery, Neurosurgery, And Other Applications), By End-User (Ambulatory Surgery Centers, Specialty Clinics, And Hospitals), And By Region – Global And Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, And Forecasts 2022 – 2028 "into their research database. Tissue Sealants and Tissue Adhesive Market: Overview Sealants are materials used by surgeon to heal tissue that has been injured by a surgery or injury. Skin, internal organs, and blood vessels are among the tissues that have been damaged. Sealants are used in combination with mechanical procedures like sutures and staples to assist minimize blood loss and avoiding leaks. Tissue adhesives are liquid monomers that, when exposed to a moist surface (skin), begin an exothermic reaction, transforming into a polymer that establishes a strong tissue connection. Get a Free Sample Report with All Related Graphs & Charts (with COVID 19 Impact Analysis): Our Free Sample Report Includes: 2022 Updated Report Introduction, Overview, and In-depth industry analysis COVID-19 Pandemic Outbreak Impact Analysis Included 166 + Pages Research Report (Inclusion of Updated Research) Provide Chapter-wise guidance on Request 2022 Updated Regional Analysis with Graphical Representation of Size, Share & Trends Includes an Updated List of tables & figures Updated Report Includes Top Market Players with their Business Strategy, Sales Volume, and Revenue Analysis Zion Market Research methodology Industry Dynamics: Tissue Sealants and Tissue Adhesive Market: Growth Drivers Increase in number of orthopedic and cardiovascular procedures to foster the market. Over the forecast period, rising cardiovascular and orthopedic surgeries are expected to drive revenue growth in the global tissue sealants and tissue adhesive market. The ease of availability of novel tissue adhesives and tissue sealants among end users, combined with rising disposable money, is a major driver in the global increase in such procedures. Adhesives are essential in general surgery. Natural and manufactured polymeric materials can be used to create three-dimensional networks that adhere to target tissues chemically and physically, acting as adhesives, sealants, or hemostats. Because adhesives and sealants are such an important aspect of general surgery, demand for them will rise as the number of procedures performed increases. As a result, market growth is likely to be boosted . Tissue Sealants and Tissue Adhesive Market: Restraints Less market penetration for tissue sealants and adhesives in developing countries hinders the growth. The market's growth is also likely to be hampered by the dearth of acceptance of tissue glue and bio-adhesive sealants in developing markets. This is due to a lack of knowledge about the advantages, cost-effectiveness, therapeutic application, and reliability of tissue adhesive and tissue sealants against alternative procedures or products, as well as tissue healing therapies. Directly Purchase a Copy of the Report @ Global Tissue Sealants and Tissue Adhesive Market: Opportunities Technological advancement for product launches creates numerous opportunities for market growth. Companies have been working on the development of novel tissue glue and bio-adhesive sealants to reach a variety of consumers, including toddlers, and young and elderly patients, during the last few years. Tissue sealants are currently used to protect sensitive, fragile, skin from damage, and to prevent cross-contamination & infection transmission. For innovative product launches, major companies are investing heavily in R&D activities. All such factors are likely to generate numerous opportunities for the global tissue sealants and tissue adhesive market growth during the forecast period. Global Tissue Sealants and Tissue Adhesive Market: Challenges Limitations in the development of tissue adhesive to act as a major challenge for the market growth. Despite the fact that many tissue adhesives form strong connections with tissue, they are frequently not designed for specific tissue applications. Tissue adhesives, in particular, do not biodegrade at a rate consistent with tissue repair, cause an unwanted inflammatory response upon adhesion or disintegration, fail to cohere in high-load-bearing applications, or do not match the characteristics of the underlying tissue. In the early stages of development, rigorous differentiation of target applications and greater in-depth investigation of tissue-surface features and tissue-environmental parameters are necessary. Despite the fact that the surface of the tissue and the surrounding environment change amongst tissues, the most typical technique is to utilize one type of adhesive for all conceivable tissues. This "one-size-fits-all" approach frequently results in tissue adhesive misuse, leading to inferior performance and dampening enthusiasm for potentially promising new materials. This could also lead to an incorrect cost-effectiveness analysis for specified unmet clinical requirements in the early stages of development, culminating in an exaggeration of cost in later stages of development and obstructing clinical translation. A failure to understand the physiological effects of adhesive materials after implantation is another factor for the research-to-product mismatch. All such limitations may pose challenges to market growth . Global Tissue Sealants and Tissue Adhesive Market: Segmentation The global tissue sealants and tissue adhesive market is categorized based on product, application, end-user, and region. Based on the product, the market is divided into semi-synthetic & synthetic adhesives and biological or natural sealants. The application segment consists of neurosurgery, cosmetic surgery, cardiovascular surgery, gynecology surgery, orthopedic surgery, general surgery, and other applications. The end-user segment is bifurcated into ambulatory surgery centers, specialty clinics, and hospitals. Get More Insight before [email protected]: List of Key Players inTissue Sealants and Tissue Adhesive Market: Integra LifeSciences C.R Bard Smith & Nephew Exapharma Johnson & Johnson Baxter International Inc. Tissuemed Ltd. Chemence Medical Inc. Cohera Medical Inc. Luna Innovations Incorporated Key questions answered in this report: What are the growth rate forecast and market size for Tissue Sealants and Tissue Adhesive Market? What are the key driving factors propelling the Tissue Sealants and Tissue Adhesive Market forward? What are the most important companies in the Tissue Sealants and Tissue Adhesive Market Industry? What segments does the Tissue Sealants and Tissue Adhesive Market cover? How can I receive a free copy of the Tissue Sealants and Tissue Adhesive Market sample report and company profiles? Report Scope: Free Brochure: Recent Developments: In January 2020, Polyganics, a medical technology business that develops, manufactures, and sells bioresorbable medical devices, revealed that LIQOSEAL®, its effortless and unique dural sealant patch, has received CE certification and will be available in Europe immediately. In December 2019, Johnson & Johnson Medical Devices Companies announced that Ethicon has released VISTASEAL Fibrin Sealant (Human) to assist surgeons minimize bleeding during surgery. VISTASEAL Fibrin Sealant (Human) is made up of fibrinogen and thrombin, which are both clotting proteins present in human plasma. It creates a fast, adherent, and permanent clot after placed on the bleeding site and has been shown to maintain hemostasis (blood stoppage) in high-risk patients. Regional Dominance: North America is the leader in the global market. Among the regions, North America is estimated to lead the global tissue sealants and tissue adhesive market during the forecast period. Because of its large population and technical advancements, North America accounted for the largest share of tissue sealants and tissue adhesive. However, the market for tissue sealants and tissue adhesives is expected to expand significantly in Asia Pacific countries. Factors such as state-of-the-art medical research facilities and rising investments in healthcare infrastructure in this region, and also heightened understanding among both physicians & patients relating therapeutic approaches, enhanced life expectancy, and a rising population will push growing demands for tissue sealants and tissue adhesives in Asia Pacific region. Global Tissue Sealants and Tissue Adhesive Market is segmented as follows: Tissue Sealants and Tissue Adhesive Market:ByProduct Outlook(2022-2028) Natural or Biological Sealants and Adhesives Synthetic and Semi-Synthetic Adhesives Tissue Sealants and Tissue Adhesive Market: By ApplicationOutlook (2022-2028) General Surgery Orthopedic Surgery Gynecology Surgery Cardiovascular Surgery Cosmetic Surgery Neurosurgery Other Applications Tissue Sealants and Tissue Adhesive Market: By End-user Outlook (2022-2028) Hospitals Specialty Clinics Ambulatory Surgery Centers Tissue Sealants and Tissue Adhesive Market:By Region Outlook(2022-2028) North America The U.S. Canada Europe France The UK Spain Germany Italy Rest of Europe Asia Pacific China Japan India South Korea Southeast Asia Rest of Asia Pacific Latin America Brazil Mexico Rest of Latin America Middle East & Africa GCC South Africa Rest of Middle East & Africa Browse Other Related Research Reports from Zion Market Research Orthopedic Navigation Systems Market - Global Industry Analysis : The global Orthopedic Navigation Systems market accrued earnings worth approximately 2.1(USD Billion) in 2020 and is predicted to gain revenue of about 7.3 (USD Billion) by 2028, is set to record a CAGR of nearly 14.7% over the period from 2021 to 2028. Intravenous Infusion Pumps Market - Global Industry Analysis : The global Intravenous Infusion Pumps market accrued earnings worth approximately 4.7 (USD Billion) in 2020 and is predicted to gain revenue of about 8.9 (USD Billion) by 2028, is set to record a CAGR of nearly 8.1% over the period from 2021 to 2028. Disposable Hospital Gowns Market - Global Industry Analysis : The global Disposable Hospital Gowns market accrued earnings worth approximately 2.02 (USD Billion) in 2020 and is predicted to gain revenue of about 5.72 (USD Billion) by 2028, is set to record a CAGR of nearly 13.8% over the period from 2021 to 2028. Browse through Zion Market Research's coverage of the Global Medical Device Industry Follow Us on: LinkedIn | Twitter | Facebook About Us Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, and company reports to country report. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client's needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us . Contact Us: Zion Market Research 244 Fifth Avenue, Suite N202 New York, 10001, United States Tel: +49-322 210 92714 USA/Canada Toll Free No.1-855-465-4651 Email: [email protected] Website: Blog - Logo: SOURCE Zion Market Research

100 Deals associated with Fibrin Sealant (Baxter)

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Hemorrhage	United States	Baxter Healthcare Corp.	07 Feb 2000

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hemorrhage	Discovery	Germany	Baxter Innovations GmbH	01 Nov 2010

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02891070 (CTgov)	Phase 3	Cerebrospinal Fluid Leak	224	Tisseel (Tisseel)	kkvprvznkp(jntdfttssk) = xfbubpodrb pcstuzwvqf (xmodvlsltu, hxcofzpwaz - djorphcbio) View more	-	10 Sep 2019
				Sealant (DuraSeal)	kkvprvznkp(jntdfttssk) = hblpxjxjtt pcstuzwvqf (xmodvlsltu, ctrhdjqvmd - kezcufnilh) View more
NCT01613664 (Pubmed \| Ann Surg)	Phase 3	-	586	Fibrin Sealant	aajxnidlbi(hfqjisgsrg) = ozihdwayms ncauzwdebi (dvlogqsrnd ) View more	-	01 Nov 2018
				Fibrin Sealant (Control (without FS))	aajxnidlbi(hfqjisgsrg) = jgykrsvgdi ncauzwdebi (dvlogqsrnd ) View more
ARVO2013	Not Applicable	Pterygium	96	Evicel	(tzejgfljmg) = jsrmytwina jslspnovag (pdrentithq ) View more	Positive	01 Jun 2013
				Tisseel	(tzejgfljmg) = noyqhtufuq jslspnovag (pdrentithq ) View more
NCT01244425 (CTgov)	Phase 2	Hemorrhage	70	Fibrin Sealant (FS) VH S/D 500 s-apr (FS VH S/D 500 S-apr)	cjeauvidpw(vpuftsfcnw) = reumtqzbit yjdcspeole (bqgpjkrniw, codppozdyb - yxbtefhbjy) View more	-	12 Feb 2013
				Manual compression (Manual Compression - Control)	cjeauvidpw(vpuftsfcnw) = vcvtuqakri yjdcspeole (bqgpjkrniw, nbhbkvexvt - augziofmvb) View more
NCT00324272 (CTgov)	Phase 4	Melanoma \| Squamous Cell Carcinoma	74	Fibrin Sealant (Tisseel) used in the Experimental Arm. (Groin Dissection: Sealant Used.)	hrbburxnqc(dfsqnrhqfe) = jnvzxoutuh uxzywnczsf (jpuformbbs, bckmmcfspl - lcfqtrcbjy) View more	-	11 Aug 2011
				Fibrin Sealant (Tisseel) used in the Experimental Arm. (Groin Dissection: no Sealant Used.)	hrbburxnqc(dfsqnrhqfe) = qgvslyoohn uxzywnczsf (jpuformbbs, szavkjgrve - eehauzldaa) View more
PO491 (AAO2008)	Not Applicable	Conjunctival Diseases	60	Fibrin sealant	(wjfggxigoe) = kfugbjtyvs smteckjmuq (xsxuidijxj ) View more	Positive	10 Nov 2008
				Fibrin Sealant	(wjfggxigoe) = nrzslewgqa smteckjmuq (xsxuidijxj ) View more
AAO2008	Not Applicable	Pterygium	192	Tisseel	(pnifwgpltn) = xqfjegtwvl mkioydgdix (ycswgynhcc )	Positive	09 Nov 2008
Gynecologic Oncology Group study (Pubmed \| Gynecol Oncol)	Phase 3	-	150	VH fibrin sealant (Sutured closure)	kkcejqnqws(wlhewyiaht) = rbdbxaztie ejhvftmgpl (ntigxgzsay ) View more	Negative	01 Jul 2008
NCT00506311 (Pubmed \| World J Surg Oncol)	Not Applicable	-	30	Fibrin sealant	ddcnmcjuwg(lcgftlqjqz) = jrggwwdzuq ntbxwbtrgu (smflfrmios )	Negative	18 Jun 2008
				Fibrin sealant (Control group)	ddcnmcjuwg(lcgftlqjqz) = gxmjssuuek ntbxwbtrgu (smflfrmios )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis